AI assistant
ArcticZymes Technologies — Regulatory Filings 2017
Aug 29, 2017
3538_iss_2017-08-29_6e7e94ac-3475-43fa-835e-4312d8faf7bb.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Press release
Biotec has prolonged supply agreement for delivery of M-Glucan
(Tromsø 29. August 2017) Biotec Pharmacon ASA's (OSE:BIOTEC) subsidiary Biotec BetaGlucans AS has today prolonged a supply agreement with an existing feed customer for deliveries of its beta-glucan product M-Glucan® for use in animal health
Deliveries under the agreement will continue from this day and run until 30th June 2018 with 6 months renewal option. Expected revenues for the first period is around NOK 25 million depending on their sales.
"We are very pleased to prolong this agreement as it secures substantial sales within animal feed. It confirms Biotec's position as a market leader within sales of beta-glucan products to animal health, says Svein W. F. Lien, CEO, Biotec Pharmacon.
For additional information: Børge Sørvoll CFO +47 952 90187 [email protected]
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel immunomodulating products, including Woulgan®, a premium priced product in the advanced wound care market. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics.